Sign in
4

Changes in Ownership

Summit Therapeutics Inc. Filed Acc 0001193805-20-001473

Chief Scientific Officer sold 30,431 shares at an average $4.30 ($130,770)

  • Chief Scientific Officer acquired 30,431 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Powell David Jonathan · Chief Scientific Officer

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2020-11-23 Exercise or conversion : show line 1 in the form +6,987 $1.92 $13,415 6,987 D
2020-11-23 Sale : show line 2 in the form −6,987 $4.40 $30,743 0 D
2020-11-24 Exercise or conversion : show line 3 in the form +11,374 $1.92 $21,838 11,374 D
2020-11-24 Sale : show line 4 in the form −11,374 $4.21 $47,885 0 D
2020-11-25 Exercise or conversion : show line 5 in the form +12,070 $1.92 $23,174 12,070 D
2020-11-25 Sale : show line 6 in the form −12,070 $4.32 $52,142 0 D
Open-market sales · 30,431 sh · avg $4.30 · $130,770

Table II: Derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2020-11-23 Option exercise : show line 7 in the form Stock Option (right to buy) −6,987 $1.92 $13,415 457,699 D
2020-11-24 Option exercise : show line 8 in the form Stock Option (right to buy) −11,374 $1.92 $21,838 446,325 D
2020-11-25 Option exercise : show line 9 in the form Stock Option (right to buy) −12,070 $1.92 $23,174 434,255 D
Loading xslF345X03/e620105_4-powell.xml…